Hot Selling API 99% Raw Material CAS 1985606-14-1 Xofluza Baloxavir Marboxil Powder 

Introduction

Product Name:Baloxavir Marboxil

Synonyms:Xofluza;aloxavir marboxil
CAS No. 1985606-14-1
EINECS: 606-227-7
Molecular Formula: C27H23F2N3O7S
Molecular Weight: 571.55
Specification: 98%
Appearance:White powder

Boiling Point :712.8±70.0 °C(Predicted)

Density :1.57±0.1 g/cm3(Predicted)

Storage:Keep in dark place,Sealed in dry,Room Temperature

Baloxavir marboxil is a white crystalline powder. Baloxavir marboxil is a new hat-dependent endonuclease inhibitor that kills influenza viruses within 24 hours, but some symptoms can last longer. Baloxavir marboxil inhibits virus replication by different mechanisms from existing anti-flu drugs. Oseltamivir (tamiflu), which is snapped up during flu, Baloxavir marboxil usually takes 72 hours to work.
Unlike neuraminidase inhibitors such as oseltamivir (tamiflu), baloxavir marboxil prevents virus replication by inhibiting cap - dependent endonuclease activity of viral polymerases.

Function 

Baloxavir marboxil is used to treat influenza A and influenza B infections. The drug was initially approved for marketing in Japan in February 2018, and was approved by the FDA on October 24, 2018 for the treatment of acute uncomplicated influenza patients 12 years of age and older who have symptoms for no more than 48 hours. Baloxavir marboxil is a cap endonuclease inhibitor, which has a unique mechanism of action compared with the class of neuraminidase inhibitor drugs currently used to treat influenza infections.